Trial intelligence / Profile preview

Venetoclax plus azacitidine for higher-risk myelodysplastic syndrome (China, single-arm)

ChiCTR2200056993Phase 4Recruiting

Sponsor
First Affiliated Hospital, Zhejiang University School of Medicine
Start
Jun 2021
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of venetoclax and azacitidine in myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: overall response rate. Started Jun 2021; status: recruiting.

02

Drugs

venetoclaxazacitidine
03

Conditions

myelodysplastic syndrome (MDS)

Beyond the preview

Go deeper on ChiCTR2200056993.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2200056993.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call